See more : Laser Photonics Corporation (LASE) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroPace, Inc. (NPCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroPace, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Ten Lifestyle Group Plc (TENG.L) Income Statement Analysis – Financial Results
- Jones Tech PLC (300684.SZ) Income Statement Analysis – Financial Results
- Oshidori International Holdings Limited (0622.HK) Income Statement Analysis – Financial Results
- Grove Collaborative Holdings, Inc. (GROV) Income Statement Analysis – Financial Results
- Arfin India Limited (ARFIN.BO) Income Statement Analysis – Financial Results
NeuroPace, Inc. (NPCE)
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 65.42M | 45.52M | 45.18M | 41.14M | 36.97M |
| Cost of Revenue | 17.30M | 13.03M | 11.75M | 10.87M | 10.51M |
| Gross Profit | 48.12M | 32.49M | 33.44M | 30.27M | 26.46M |
| Gross Profit Ratio | 73.56% | 71.38% | 74.00% | 73.59% | 71.58% |
| Research & Development | 20.78M | 21.95M | 18.21M | 15.70M | 18.29M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.52M | 51.34M | 38.96M | 27.63M | 30.20M |
| Other Expenses | 0.00 | -337.00K | -5.38M | 218.00K | 1.28M |
| Operating Expenses | 75.30M | 73.29M | 57.17M | 43.32M | 48.50M |
| Cost & Expenses | 92.60M | 86.31M | 68.92M | 54.19M | 59.00M |
| Interest Income | 3.05M | 1.58M | 448.00K | 41.00K | 261.00K |
| Interest Expense | 8.52M | 7.53M | 7.41M | 11.49M | 9.49M |
| Depreciation & Amortization | 1.61M | 2.99M | 296.00K | 312.00K | 421.00K |
| EBITDA | -22.83M | -36.57M | -28.37M | -12.48M | -20.07M |
| EBITDA Ratio | -34.90% | -86.89% | -62.80% | -30.34% | -54.28% |
| Operating Income | -27.17M | -40.79M | -23.74M | -13.05M | -22.03M |
| Operating Income Ratio | -41.54% | -89.62% | -52.54% | -31.72% | -59.59% |
| Total Other Income/Expenses | -5.78M | -6.29M | -12.34M | -11.23M | -7.94M |
| Income Before Tax | -32.96M | -47.08M | -36.08M | -24.28M | -29.97M |
| Income Before Tax Ratio | -50.38% | -103.43% | -79.85% | -59.02% | -81.07% |
| Income Tax Expense | 0.00 | 6.29M | 2.03M | 11.70M | 10.77M |
| Net Income | -32.96M | -53.37M | -38.11M | -35.98M | -40.74M |
| Net Income Ratio | -50.38% | -117.25% | -84.34% | -87.47% | -110.19% |
| EPS | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| EPS Diluted | -1.27 | -2.17 | -1.56 | -1.51 | -1.71 |
| Weighted Avg Shares Out | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
| Weighted Avg Shares Out (Dil) | 25.85M | 24.59M | 24.45M | 23.83M | 23.83M |
Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript
Neuropace, Inc. (NASDAQ:NPCE ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary...
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe...
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022...
NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming Morgan Stanley...
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2022 Results - Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Bacso - Investor Relations Mike Favet - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Larry Biegelsen -...
NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter 2022...
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q1 2022 Results - Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Bacso – Investor Relations Mike Favet – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Larry Biegelsen –...
NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital...
Bear of the Day: NeuroPace (NPCE)
EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports